Evaluating Anti-factor Xa Levels in Patients with Augmented Renal Clearance Receiving Enoxaparin Prophylaxis: An Exploratory Pilot Study
The prophylactic use of enoxaparin in patients with ARC may result in insufficient antifactor X<sub>a</sub> levels. Although the mean levels were within the target range, many individuals did not reach the target level. Healthcare providers should consider renal function and ARC when prescribing enoxaparin to prevent thromboembolic events.
Authors
- Azadeh Eshraghi (ORCID: https://orcid.org/0000-0003-2198-1162)
- Saghar Barati (ORCID: https://orcid.org/0000-0002-5620-338X)
- Zahra Sahraei (ORCID: https://orcid.org/0000-0002-0178-8624)
Institutions
- Iran University of Medical Sciences (IR)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- Journal of Research in Pharmacy Practice
- Published
- 2025-01-01
- DOI
- https://doi.org/10.4103/jrpp.jrpp_11_25
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87